Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | 6 | Seeking Alpha | ||
Di | Day One Biopharmaceuticals: Umsatzwachstum bei OJEMDA hält an, während die Entwicklungspipeline voranschreitet | 15 | Investing.com Deutsch | ||
Di | Day One Biopharmaceuticals Non-GAAP EPS of -$0.29 beats by $0.05, revenue of $33.91M misses by $0.99M | 16 | Seeking Alpha | ||
Di | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
Di | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.07. | Day One Biopharmaceuticals, Inc.: Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 | 3 | GlobeNewswire (USA) | ||
23.06. | TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN) | 7 | Insider Monkey | ||
10.06. | Day One Biopharmaceuticals, Inc.: Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development | 5 | GlobeNewswire (USA) | ||
DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
03.06. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
06.05. | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | 448 | GlobeNewswire (Europe) | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
06.05. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.04. | Day One Biopharmaceuticals, Inc.: Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 | 8 | GlobeNewswire (USA) | ||
03.04. | H.C. Wainwright maintains Buy on Day One Biopharmaceuticals | 12 | Investing.com | ||
06.03. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
26.02. | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | 8 | Investing.com | ||
25.02. | Day One Biopharmaceuticals GAAP EPS of -$1.02 misses by $0.29, revenue of $131.16M beats by $8.64M | 2 | Seeking Alpha | ||
25.02. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.02. | Day One Biopharmaceuticals, Inc.: Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 | 7 | GlobeNewswire (USA) | ||
30.10.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | 511 | GlobeNewswire (Europe) | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
CUREVAC | 4,660 | -0,09 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
AMGEN | 247,20 | -0,14 % | Amgen hebt Prognose nach überraschend gut verlaufenem Quartal an | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt nach einem überraschend gut gelaufenen Quartal optimistischer auf 2025. Der Umsatz dürfte bei 35 bis 36 Milliarden US-Dollar liegen, teilte... ► Artikel lesen | |
NOVAVAX | 7,220 | +0,36 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
BIOGEN | 111,70 | -0,49 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
CRISPR THERAPEUTICS | 46,800 | -1,27 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
MAINZ BIOMED | 1,440 | -0,69 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
VIKING THERAPEUTICS | 32,740 | +0,63 % | Eli Lilly's obesity drug data lifts Viking Therapeutics stock | ||
INTELLIA THERAPEUTICS | 9,236 | -0,39 % | Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus | ||
GENMAB | 187,00 | +0,43 % | Genmab Reports Strong H1 2025 Results Driven By Higher Royalties And Product Sales | COPENHAGEN (dpa-AFX) - Genmab A/S (GMAB) posted performance results on Thursday for the first half of 2025, with revenue rising 19 percent year-over-year to $1.64 billion, up from $1.38 billion... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,228 | +1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
TEMPUS AI | 52,00 | -0,95 % | Tempus AI: 90 Prozent Wachstum - KI-Aktie hebt ab | Das US-Unternehmen Tempus AI hat am Freitagmittag die Zahlen für das abgelaufene zweite Quartal vorgelegt. Sowohl bei Umsatz als auch Ergebnis je Aktie konnte der KI-Spezialist besser ab als vom Markt... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 15,785 | +0,80 % | What 43 Analyst Ratings Have To Say About Sarepta Therapeutics | ||
CARDIOL THERAPEUTICS | 0,850 | -0,12 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with improvements... ► Artikel lesen | |
EXELIXIS | 32,470 | +0,22 % | Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors | - Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo... ► Artikel lesen |